You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

37 Results
Guidelines and Advice
Status: Current
ID: 19-5
Version: 2
Jul 2024
Drug
Other Name(s): Afinitor®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2019
Drug
Other Name(s): Xtandi®
Quick Link(s):
Drug Monograph, Patient Info Sheet
Jun 2024
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
DACTINomycin,
etoposide,
methotrexate,
leucovorin,
cyclophosphamide,
vinCRIStine
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
EPIrubicin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2019
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Ovary
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Gynecologic, 
Gestational Trophoblastic Disease
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
PACLitaxel,
CISplatin,
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Gastrointestinal, 
Neuroendocrine (GI)
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    everolimus - For patients who have progressive, unresectable, well or moderately differentiated, locally advanced or metastatic pancreatic neuroendocrine tumors (PNET), with specific criteria
Exceptional Access Program
    everolimus - Treatment of unresectable, locally advanced or metastatic, well-differentiated non-functional neuroendocrine tumours (NETs) of GI or lung origin, according to clinical criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
everolimus
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2024
Regimen
Cancer Type:
Genitourinary, 
Bladder / Urothelial
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
ODB - General Benefit
    etoposide - oral capsules
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
etoposide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2019
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Hodgkin, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Drugs Used:
etoposide,
CISplatin,
cytarabine,
methylprednisolone
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2019

Pages